Maze Therapeutics, Inc. Common Stock • MAZE

Capital at risk.

About Maze Therapeutics, Inc. Common Stock
Ticker
info
MAZE
Trading on
info
NASDAQ
ISIN
info
US5787841007
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
Headquarters
info
171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
Employees
info
125
Website
info
mazetx.com
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Metrics
BasicAdvanced
Market cap
info
$525M
P/E ratio
info
-
EPS
info
-$0.42
Dividend Yield
info
0.00%
Beta
info
-
Forward P/E ratio
info
0
EBIDTA
info
$67.8M
Ex dividend date
info
-
Price & volume
Market cap
info
$525M
Average daily volume
info
0.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
3.14
Price to book
info
0
Earnings
EPS
info
-$0.42
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$67.8M
Revenues (TTM)
info
$168M
Revenues per share (TTM)
info
$7.33
Technicals
Beta
info
-
52-week High
info
$34.29
52-week Low
info
$6.71
50-day moving average
info
$13.10
200-day moving average
info
$13.10
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
0.00%
ROA (TTM)
info
0.00%
Profit margin
info
32.97%
Gross profit margin
info
$168M
Operating margin
info
-969.16%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
43.8M
Float
info
9.6M
Insiders %
info
11.49%
Institutions %
info
56.82%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$18.32
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-33.7M
-∞%
Q2 • 25
$-30.1M
0.00%
Q3 • 25
NaN%
-10.67%
0.00%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$304M
$41.3M
13.60%
Q2 • 25
$422M
$42.6M
10.10%
Q3 • 25
39.05%
3.25%
-25.75%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-30.1M
$-0.4M
$0.6M
$-30.4M
Q2 • 25
$-24.6M
-
$144M
$-24.7M
Q3 • 25
-18.00%
-
23,389.71%
-18.84%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Maze Therapeutics, Inc. Common Stock share?
Collapse

Maze Therapeutics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Maze Therapeutics, Inc. Common Stock have?
Collapse

Maze Therapeutics, Inc. Common Stock currently has 43.8M shares.

Does Maze Therapeutics, Inc. Common Stock pay dividends?
Collapse

No, Maze Therapeutics, Inc. Common Stock doesn't pay dividends.

What is Maze Therapeutics, Inc. Common Stock 52 week high?
Collapse

Maze Therapeutics, Inc. Common Stock 52 week high is $34.29.

What is Maze Therapeutics, Inc. Common Stock 52 week low?
Collapse

Maze Therapeutics, Inc. Common Stock 52 week low is $6.71.

What is the 200-day moving average of Maze Therapeutics, Inc. Common Stock?
Collapse

Maze Therapeutics, Inc. Common Stock 200-day moving average is $13.10.

Who is Maze Therapeutics, Inc. Common Stock CEO?
Collapse

The CEO of Maze Therapeutics, Inc. Common Stock is Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D..

How many employees Maze Therapeutics, Inc. Common Stock has?
Collapse

Maze Therapeutics, Inc. Common Stock has 125 employees.

What is the market cap of Maze Therapeutics, Inc. Common Stock?
Collapse

The market cap of Maze Therapeutics, Inc. Common Stock is $525M.

What is the P/E of Maze Therapeutics, Inc. Common Stock?
Collapse

The current P/E of Maze Therapeutics, Inc. Common Stock is null.

What is the EPS of Maze Therapeutics, Inc. Common Stock?
Collapse

The EPS of Maze Therapeutics, Inc. Common Stock is -$0.42.

What is the PEG Ratio of Maze Therapeutics, Inc. Common Stock?
Collapse

The PEG Ratio of Maze Therapeutics, Inc. Common Stock is null.